本文へ移動
cccskills
無料GitHub で公開

endo-annual-reassess-cgm-smbg-calibrate

Reassesses annually the patient’s use of self-monitoring blood glucose to calibrate the CGM system. Triggered by ‘Yearly calibration practice review’ or ‘Annual check of SMBG calibration adherence’.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.6 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Annually reassess use of SMBG to calibrate CGM

STEP 1 — Gather Information

Collect SMBG calibration frequency and timing, calibration log entries, sensor accuracy alerts, hypoglycemia/hyperglycemia events, patient-reported barriers (vision, dexterity, cognition), insurance coverage for strips, and current CGM model calibration requirements.

STEP 2 — Rule In / Rule Out

Is the patient performing SMBG calibration at least once per day (or per manufacturer’s recommendation) for the CGM system?

  • Yes → Rule In: adequate calibration practice.
  • No → Rule Out: inadequate calibration practice.

STEP 3 — Classify or Stratify

If Rule In: assess ability to make insulin adjustments based on CGM trend information (trend‑based dosing competence).
If Rule Out: classify barriers into cognitive/physical, insurance/access, or knowledge/behavioral deficits.

STEP 4 — Decide

  • If Rule In and trend‑based dosing competent: continue current CGM use with annual reassessment.
  • If Rule In but trend‑based dosing deficient: provide targeted education on interpreting CGM trends and adjusting insulin.
  • If Rule Out: address specific barriers (e.g., simplify SMBG routine, assist with strip access, consider factory‑calibrated CGM if appropriate, reinforce calibration training).

Clinical Guardrails / Mimics / Pitfalls

Do not assume calibration adequacy without reviewing logs; do not rely solely on CGM for therapy decisions on devices requiring calibration; do not discontinue SMBG without confirming the CGM is factory‑calibrated; do not overlook sensor site irritation that may deter SMBG; avoid alarm fatigue by ensuring alerts are appropriately set.

Concrete Clinical Example

A 58‑year‑old with T1D using a Dexcom G6 (requires calibration) presents for yearly review. Log shows SMBG calibration twice weekly, missing daily calibrations. Patient reports finger‑stick pain and forgetfulness. After Rule Out, barriers classified as behavioral/physical. Decision: switch to a factory‑calibrated CGM (Freestyle Libre 3) and provide brief SMBG refresher for occasional confirmation.

Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2534

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する